Watch Live

Tweet TWEET

Synergy Announces Adjournment of Annual Meeting

Synergy Announces Adjournment of Annual Meeting

NEW YORK, Jan. 3, 2013 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals, Inc.
(Nasdaq:SGYP) today announced that it convened its annual meeting of
stockholders on Thursday, January 3, 2013 and adjourned the meeting until
Monday, January 14, 2013, at 10:00 a.m., Eastern Standard Time. The annual
meeting was adjourned to allow the Company's stockholders a reasonable amount
of time to consider the information about the Company's results from its Phase
IIb/III clinical study.

The reconvened annual meeting will be held at the offices of Sichenzia Ross
Friedman Ference LLP, 61 Broadway, 32^nd Floor, New York, NY
10006.Shareholders who have already voted do not need to recast their votes.
Proxies previously submitted in respect of the meeting will be voted at the
adjourned meeting unless properly revoked. Given the adjournment, proxies may
now be received by our registrar and transfer agent, Philadelphia Stock
Transfer Inc., no later than January 13, 2013 at 11:59 p.m. (Eastern Standard
Time).

About Synergy Pharmaceuticals Inc.

Synergy is a biopharmaceutical company focused on the development of new drugs
to treat gastrointestinal disorders and diseases. Synergy's lead proprietary
drug candidate plecanatide is a synthetic analog of the human gastrointestinal
hormone uroguanylin, and functions by activating the guanylate cyclase C
receptor on epithelial cells of the GI tract. Synergy completed a Phase I
study of plecanatide in healthy volunteers, a Phase IIa clinical trial in CIC
patients, and has just completed a major Phase IIb/III clinical trial of
plecanatide to treat CIC. Plecanatide is also being developed to treat IBS-C,
with the first trial in IBS-C patients initiated in the fourth quarter of
2012. Synergy's second GC-C agonist SP-333 is in clinical development to treat
inflammatory bowel diseases, and has just completed its first Phase I trial in
healthy volunteers. More information is available at
http://www.synergypharma.com.

CONTACT: Investor Contact:
         Danielle Spangler
         The Trout Group
         synergy@troutgroup.com
         (646) 378-2924
 
Press spacebar to pause and continue. Press esc to stop.